NIH Clinical Center: Search the Studies

Search the Studies

15 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
000954-C	A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer	Participants currently recruited/enrolled	18-125 Years	NCI	Mesothelioma
000486-C	A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma	Participants currently recruited/enrolled	18-125 Years	NCI	Mesothelioma
000062-C	Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants with Pleural Mesotheliomas, or Pleural Effusions from Cancers Expressing Mesothelin	Participants currently recruited/enrolled	18-120 Years	NCI	Mesothelioma
000059-C	Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma	Participants currently recruited/enrolled	18-125 Years	NCI	Mesothelioma
21-C-0012	Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies	Participants currently recruited/enrolled	18-125 Years	NCI	Mesothelioma
20-C-0106	Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome	Participants currently recruited/enrolled	30-125 Years	NCI	Mesothelioma
19-C-0128	A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors	Completed Study; data analyses ongoing	18-125 Years	NCI	Mesothelioma
19-C-0117	A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer	Participants currently recruited/enrolled	18-120 Years	NCI	Mesothelioma
19-C-0049	Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other Genes	Participants currently recruited/enrolled	2-125 Years	NCI	Mesothelioma
18-C-0143	A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy	Completed Study; data analyses ongoing	18-125 Years	NCI	Mesothelioma
17-C-0140	Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas	Completed Study; data analyses ongoing	18-99 Years	NCI	Mesothelioma
16-C-0128	A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors	Completed Study; data analyses ongoing	18-125 Years	NCI	Mesothelioma
13-C-0202	Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers	Participants currently recruited/enrolled	2-125 Years	NCI	Mesothelioma
13-C-0131	Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular Therapy	Participants currently recruited/enrolled	18-125 Years	NCI	Mesothelioma
06-C-0014	Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies	Participants currently recruited/enrolled	2-125 Years	NCI	Mesothelioma